Table 4 Select/relevant genes with significant differential gene expression between the lipopolysaccharide-challenged control group and the unchallenged control group
From: Effects of hyaluronan treatment on lipopolysaccharide-challenged fibroblast-like synovial cells
Genbank accession number | Equine gene | Fold change (group 2/group 1) | P value |
|---|---|---|---|
AY114351 | Granulocyte chemotactic protein 2 | 10.0 | <0.0001 |
CD528275 | Interferon-induced protein | 0.03 | <0.0001 |
CD468799 | GRO3 oncogene | 10.0 | <0.0001 |
BI960809 | TNFα | 2.5 | 0.0001 |
AJ251189 | Chemoattractant protein-1 | 3.33 | 0.0016 |
CD536631 | GRO2 oncogene | 10.0 | 0.0002 |
BM734848 | Chondroitin sulfate proteoglycan 2 | 2.0 | 0.0005 |
AB035518 | Adrenomullin | 0.42 | 0.0006 |
AF230359 | Urokinase plasminogen activator receptor | 1.67 | 0.0009 |
AF053497 | Melanoma growth stimulatory activity homolog | 5.0 | 0.0014 |
AF027335 | Prostaglandin G/H synthase-2 | 3.33 | 0.0021 |
U62529 | Matrix metalloproteinase 3 | 2.0 | 0.0026 |
CD467591 | Heat shock protein 70 | 2.5 | 0.0027 |
AY056582 | Hyaluronic acid synthase 2 | 5.0 | 0.0028 |
U64794 | IL-6 | 2.0 | 0.0037 |